Observed Signal · Aug 5, 2026 · earnings · Source: SEC API · Impact: 3.4/5
10-Q Financial Filing Analysis for 1stDibs (2026-08-05)
For the second quarter ended June 30, 2026, 1stDibs reported net revenue of $23.32 million, up 5% year-over-year from $22.14 million, driven by higher Gross Merchandise Value (GMV) of $95.99 million (+6.8% YoY) despite a decline in total order volumes to 31,576. Gross margin expanded to 73.9% from 71.8% in Q2 2025. The company significantly narrowed its operating loss to $2.06 million from $5.72 million and net loss to $1.02 million from $4.31 million, largely propelled by a 34% reduction in sales and marketing expenses from performance marketing optimization and organizational restructurings. Adjusted EBITDA turned positive to $1.31 million compared to negative $1.75 million in the prior-year period. Cash, cash equivalents, and short-term investments stood at $67.72 million following $20.73 million deployed in share repurchases during the first half of 2026.
Demonstrates successful operational leverage and marketing efficiency returning the luxury marketplace to positive Adjusted EBITDA despite ongoing macroeconomic and housing market headwinds.
Track 1stDibs Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Q2 2026 net revenue increased 5.3% year-over-year to $23.32 million, while gross margin expanded 210 basis points to 73.9%.
- Net loss decreased substantially to $1.02 million from $4.31 million in Q2 2025, driven by a $2.76 million drop in sales and marketing expenditures, achieving positive Adjusted EBITDA of $1.31 million.
- During the first six months of 2026, 1stDibs completed its 2025 and 2026 repurchase programs, buying back 4,141,020 shares for $20.73 million and reducing cash and investments to $67.72 million.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
10-Q Financial Filing Analysis for Vivid Seats (2026-08-04)
Vivid Seats reported Q2 2026 financial results reflecting continued operational headwinds and a broader industry slowdown in discretionary live-event spending. Total consolidated revenues for the quarter fell 10% year-over-year to $129.86 million, driven by a 9% contraction in Marketplace revenues to $103.95 million and an 11% decline in Resale revenues to $25.91 million. Marketplace Gross Order Value (GOV) declined 4% to $659.36 million, mitigated slightly by higher average sports order values related to the 2026 FIFA World Cup. Operating loss improved to $(6.44) million compared to $(331.73) million in Q2 2025, which had been burdened by $320.45 million in goodwill and trademark impairment charges. Net loss narrowed to $(14.32) million from $(263.33) million, supported by aggressive cost-reduction measures and headcount rationalization.
10-Q Financial Filing Analysis for Cognizant (2026-07-29)
Cognizant Technology Solutions reported financial results for Q2 2026, delivering quarterly revenues of $5.48 billion, representing a 4.5% year-over-year increase (4.1% in constant currency). Revenue expansion was supported by large deal ramp-ups, growing demand in AI, analytics, and intuitive operations, as well as inorganic contributions from recent acquisitions including 3Cloud and Astreya Partners. Operating income grew 7.0% year-over-year to $874 million, yielding an operating margin of 15.9%, bolstered by operational efficiencies and foreign currency tailwinds, offset by compensation increases and dilution from acquisitions. During the quarter, Cognizant launched 'Project Leap', a multi-faceted restructuring initiative designed to accelerate AI-enabled delivery and optimize workforce productivity, incurring $84 million in restructuring charges with anticipated total program costs of $230 million to $320 million in 2026. This was counterbalanced by an $81 million reversal of an India Defined Contribution Obligation liability. The company also returned substantial capital to shareholders, repurchasing $1.15 billion in Class A common stock during the quarter.
10-Q Financial Filing Analysis for CVS Health (2026-08-05)
CVS Health Corporation reported strong financial results for the second quarter of 2026, driven by top-line growth across all major operating segments. Total revenues increased 7.3% year-over-year to $106.10 billion, up from $98.92 billion in Q2 2025. Operating income saw a substantial 97.5% increase to $4.70 billion, compared to $2.38 billion in the prior-year period, primarily supported by core operational improvements and the absence of $833 million in legacy litigation charges incurred in Q2 2025. Net income attributable to CVS Health rose significantly to $2.98 billion ($2.31 diluted EPS) from $1.02 billion ($0.80 diluted EPS). Performance in the Health Care Benefits segment reflected improved medical loss dynamics, with the Medical Benefit Ratio (MBR) declining to 87.4% from 89.9% in Q2 2025, driven by improved underlying Government business performance and the absence of prior-year premium deficiency reserves. Growth was supported by the Health Services segment, where revenues climbed 11.5% to $51.80 billion, and Pharmacy & Consumer Wellness, which posted a 2.9% increase in pharmacy same-store sales aided by Rite Aid file acquisitions. In regulatory matters, CVS reached a proposed settlement with the FTC to resolve outstanding PBM and pharmacy inquiries.
Receive all future signals for 1stDibs & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.